🔗 Share this article

Given that the US continues making unprecedented adjustments to its vaccination guidelines, an unexpected name appears in a surprising turn: Høeg, a US-based physician and public health researcher who first made her name by questioning COVID-19 shots in the pandemic and has concentrated on potential deaths following COVID-19 immunization in her short time at the Food and Drug Administration.

Proposed Overhauls to Pediatric Immunization Schedule

Agency leaders had intended to unveil radical revisions to the childhood vaccination calendar earlier this month, synchronizing the US with the Danish national calendar, according to reports – a significant shift that would place the US at odds with much of the global community with insufficient data for public health gain. This reveal has been pushed back until the coming year.

Rather than the top vaccines chief, Tracy Beth Høeg is scheduled to present at the gathering. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth appointee to run the division this year.

A New Direction at the Regulatory Body

Høeg's temporary position might represent a tighter collaboration between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad solidify control at the FDA – and it suggests a greater focus upon rolling back long-standing vaccines at the FDA.

Høeg has frequently advocated for ending specific childhood immunization guidelines in the US in order to be more similar to Denmark, a country with universal health coverage and a population approximately the size of the state of Wisconsin.

In her initial public appearances, she has kept her attention on vaccines – traditionally the purview of Dr. Prasad, head of the FDA’s CBER – as opposed to drug regulation.

Concerns Over Expertise

The appointee has no obvious track record in pharmaceutical research, regulation or management, which has been customary for previous directors of the biologics center. She has served at the FDA as a key advisor to the commissioner and CBER since spring.

“She appears not to have any of the qualifications” for running the CDER, said a neurologist and psychiatrist. “She has not conducted a scientific study. She is not versed in leading a major agency. She has no expertise in drug approvals.”

Previous commissioners of the center would “understand laws and regulations and the underlying principles of drug development”, commented a former acting FDA commissioner. “Clearly, she has not acquired the kind of background that former directors who led the center have had.”

CDER has an immense workload at the agency, she emphasized.

“The public just focuses on the novel medication approvals, but the generic program authorizes thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, over-the-counter program and so forth, and every single one have to be managed,” Woodcock noted. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Furthermore, a major administrative aspect to the position, which supervises in excess of 5,000 personnel. “It’s a massive administrative position, if you perform it correctly,” the former official said.

Official Statement and Contentious Policies

In response to inquiries about Høeg’s qualifications and whether this assignment signifies increased cooperation among FDA leaders on immunizations, a representative stated that the “concerns stem from inaccurate assumptions”.

“Her resume is consistent with the responsibilities of her job,” the official stated, pointing to the time Høeg spent counseling the agency head on “drug safety and approval science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Høeg inherits the commissioner’s recently launched priority voucher program, a controversial rapid drug-approval program that reportedly worried her predecessors. “How are these drugs being chosen for this expedited pathway? Who takes the choices?” Howard questioned. “There’s a lot of confidentiality going on at the agency right now.”

In general, he stated, “the Food and Drug Administration seems to be moving towards more relaxed regulations of all drugs, except for vaccines.”

Documented Track Record on Vaccines

With immunizations, Høeg has a more established, if concerning, track record, some experts said. She authored a analysis using unconfirmed public submissions to assess the incidence of heart inflammation following Covid immunization. She counseled the Florida surgeon general Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccines are pose a greater threat than they are.

Among her “wish list” for the current administration included revising rules for novel immunizations and discontinuing “non-essential” vaccines, she said following the vote on a podcast. At the agency, Dr. Høeg has allegedly proposed excluding teenage boys from getting Covid vaccinations.

“She’s an all-around true believer who begins with her conclusions and tailors the evidence to fit the data in a highly deceptive, dishonest fashion,” Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg aligned with fellow skeptics, {like|